Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology-Reference-Cited by-同舟云学术

Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology

Published:2017-07-01 Issue:7 Volume:3 Page:996
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Kuderer Nicole M.¹,Burton Kimberly A.¹,Blau Sibel²,Rose Andrea L.²,Parker Stephanie²,Lyman Gary H.³,Blau C. Anthony⁴

Affiliation:

1. Department of Medicine, University of Washington, Seattle2Center for Cancer Innovation, University of Washington, Seattle

2. Center for Cancer Innovation, University of Washington, Seattle3Northwest Medical Specialties, Puyallup, Washington

3. Department of Medicine, University of Washington, Seattle4 Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, Washington

4. Department of Medicine, University of Washington, Seattle2Center for Cancer Innovation, University of Washington, Seattle5Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 133 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molekulare Tumorboards in der Uroonkologie – Prostatakarzinom;Die Urologie;2024-08-06

2. Genomic alterations and transcriptional phenotypes in circulating tumor DNA and matched metastatic tumor;2024-06-03

3. Circulating Biomarkers Predictive of Treatment Response in Patients with Hormone-sensitive or Castration-resistant Metastatic Prostate Cancer: A Systematic Review;European Urology Oncology;2024-05

4. Liquid biopsy for breast cancer and other solid tumors: a review of recent advances;Breast Cancer;2024-03-16

5. Circulating Tumor DNA Detection Technology and Its Application Value in Cancer Diagnosis and Treatment;PROG BIOCHEM BIOPHYS;2024